BTK Inhibitor Dosing for High Inhibition With Lower Toxicity

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Patients treated with Bruton's tyrosine kinase (BTK) inhibitors for cancer and autoimmune diseases often become refractory or intolerant due to severe adverse events and toxicities, necessitating the development of alternative therapies with better tolerability profiles and reduced adverse effects.

Innovation Solution

Administration of (S)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropane-2-yl)-1H-pyrazole-4-carboxamide (BTK-I) or its pharmaceutically acceptable salts, in doses ranging from 120 mg to 600 mg daily, potentially combined with BCL-2 inhibitors and anti-CD20 therapies, to inhibit BTK and manage B-cell mediated cancers and autoimmune diseases.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If the dose of ibrutinib is increased to overcome resistance, then BTK inhibition efficacy is improved, but toxicities and adverse events worsen

Engineering Contradiction:

ImproveBTK inhibition efficacyVSAvoidtoxicities and adverse events

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies parameter changes by modifying the chemical structure of BTK inhibitors to achieve different potency levels. Specifically, it compares ibrutinib (420 mg daily) with acalabrutinib (100 mg daily), demonstrating that structural modifications can maintain or improve BTK inhibition efficacy while reducing toxicities and adverse events through optimized dosing parameters.

Inventive Principle:

Principle #35Parameter changes

2Adaptability or versatility

If alternative BTK inhibitors are developed for resistant patients, then treatment options are improved, but tolerability profiles may worsen

Engineering Contradiction:

Improvetreatment optionsVSAvoidtolerability profiles

Core Design Contradiction:

Adaptability or versatilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies local quality by achieving selective BTK inhibition through precise molecular design. The inhibitors are engineered to specifically target BTK with high selectivity, thereby improving adaptability for resistant patients while minimizing off-target effects and tolerability issues through localized action on the intended target.

Inventive Principle:

Principle #3Local quality

3Productivity

If BTK inhibitors are administered to achieve maximum inhibition, then therapeutic effect is improved, but adverse events and dose interruptions worsen

Engineering Contradiction:

Improvetherapeutic effectVSAvoidadverse events and dose interruptions

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

The patent applies partial or excessive action by achieving sufficient BTK inhibition at optimized doses rather than maximum doses. The data shows that acalabrutinib at 100 mg daily achieves greater than 90% BTK inhibition, which is the partial action needed for therapeutic effect while avoiding the excessive dosing that would cause adverse events and dose interruptions.

Inventive Principle:

Principle #16Partial or excessive action

Data Source

PatentUS12551463B2Dosing of a Bruton's tyrosine kinase inhibitor

Publication Date: 2026.02.17 LOXO ONCOLOGY INC

AI summary

The present invention provides a method of administering doses of the BTK inhibitor, (S)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropane-2-yl)-1H-pyrazole-4-carboxamide or a pharmaceutically acceptable salt thereof for use in treating conditions such as cancer and autoimmune diseases.